Epidemiological analysis of adult-type diffuse lower-grade gliomas and incidence and prevalence estimates of diffuse IDH-mutant gliomas in France - 20/12/24
, Valérie Rigau b, c, d, Bertrand Mathon e, f, Amélie Darlix b, c, gWith the participation of the Société Française de Neurochirurgie (SFNC), Club de Neuro-oncologie of SFNC, Société Française de Neuropathologie (SFNP) and Association des Neuro-Oncologues d’Expression Française (ANOCEF)
Highlights |
• | The main factors that impact glioma overall and diffuse lower-grade glioma incidences are reviewed. |
• | Estimate of the 2024 French glioma incidence is 6.6/100,000 person-years. |
• | For the first time we provided incidence and prevalence estimates of diffuse IDH-mutant glioma in France. |
• | French incidence estimates of diffuse IDH-mutant gliomas are 1, 0.5, 0.3, 0.2, for all grade, grade 2, grade 3, grade 4 /100,000 person-years, respectively. |
• | Grade 2 IDH-mutant glioma prevalence would be greater than 6.57/100,000 persons. |
Abstract |
Background |
The recent advent of anti-IDH therapies and changes in the WHO classification of gliomas implies estimating the number of patients who could benefit (or not) from anti-IDH treatment. As published data on the current incidence of different subtypes of IDH-mutant gliomas (based on the latest histomolecular WHO classification) are lacking in many countries. The present analysis aims to review the main factors impacting the incidence of gliomas and lower-grade gliomas and to estimate the incidence and prevalence of IDH-mutant gliomas in France.
Methods |
Our analysis was based on data from the French Brain Tumor DataBase and literature.
Results |
Case definition, recording methods, histological classifications, age, sex, ethnicity, ancestry, environment, genetics, etc., impact the incidence of gliomas overall and lower-grade gliomas. In France, for the year 2024, the incidence estimates of all gliomas and all adult-type diffuse IDH-mutant gliomas are 6.6/100,000 and 1/100,000 person-years, respectively. The incidence estimates of grades 2, 3, and 4 diffuse IDH-mutant gliomas are 0.5, 0.3, 0.2 per 100,000 person-years, respectively. Of note, the incidence estimate of grade 3 diffuse IDH-mutant glioma versus grade 2 or 4 is slightly more difficult to assess due to the possible variability in histological criteria to define tumor grade. The prevalence of diffuse IDH-mutant grade 2 glioma would be more than 6.57/100,000 persons.
Discussion/Conclusion |
Our epidemiological analysis provides estimates of potential number of patients, but large prospective real-world studies are required to determine the positioning of anti-IDH treatments among all therapeutic strategies [surgery(ies), chemotherapy(ies), radiotherapy(ies), clinical/radiological follow-up, etc.].
Le texte complet de cet article est disponible en PDF.Keywords : IDH-mutant astrocytoma, IDH-mutant and 1p/19q codeleted oligodendroglioma, IDH-mutant glioma, incidence, prevalence, survival
Abbreviations : ANOCEF, CBTRUS, CNS, INCa, INSEE, FBTDB, FRANCIM (réseau français des registres des cancers), IDH, OBTS, RnhTPSNC, SFNC, SPF, TCGA, WHO
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?